CMS Issues Final Decision
CEO Update
Alzheimer's Association
This message is sent to Alzheimer's Association volunteers, advocates and supporters.
Yesterday, the Centers for Medicare & Medicaid Services (CMS) released
its final decision on coverage for a new class of drugs addressing the
underlying biology of Alzheimer's disease. We are deeply
disappointed with the immediate impact this decision will have on
Americans living with Alzheimer's and their families. Our full
statement on the CMS decision is here.
[link removed]
As you may recall, the first of these treatments - aducanumab or
Aduhuelm - was approved by the U.S. Food and Drug Administration
(FDA) last June under the Accelerated Approval Pathway. At no time in
history has CMS imposed such drastic barriers to access FDA-approved
treatments for people facing a fatal disease.
We believe that people with Alzheimer's should have FDA-approved
treatments covered by Medicare just as those facing other diseases do.
Each individual who could benefit, in your family and in every family,
deserves the opportunity to choose such treatment in consultation with
that individual's doctor.
Still, some of the recommendations provided by people living with
Alzheimer's and the Alzheimer's Association have been
incorporated into the CMS decision. CMS has decided to utilize a
registry for future treatments granted full FDA approval. We know that
the recently announced Alzheimer's Association registry will
play an important role in collecting and analyzing real-world data.
Similar registries have been successful in heart disease and cancer.
Our work is far from done. The Alzheimer's Association is here
for you and your family today and every day to provide care and
support through our programs, resources and 24/7 helpline. Our
constituents remain at the center of everything we do and we will
continue to work relentlessly to ensure equitable access to quality
care including all current and future FDA-approved treatments and
diagnostic tests needed for all individuals with Alzheimer's
disease.
Thank you so much for everything you have done and continue to do. We
will remain relentless together.
Harry Johns Signature
Harry Johns
Chief Executive Officer
CONNECT WITH US
Facebook
Twitter
Pinterest
Blog
[link removed]
[link removed]
[link removed]
[link removed]
Alzheimer's Association
Alzheimer's Association
225 N. Michigan Ave., FL 17, Chicago, IL
60601
800.272.3900 | alz.org
tel:800.272.3900
[link removed]
© 2022 Alzheimer's Association. All rights
reserved. Alzheimer's Association is a not-for-profit 501(c)(3)
organization.
Contact Us
|
Privacy Policy
|
Unsubscribe
[link removed]
[link removed]
[link removed]
To unsubscribe from all future email, paste the following URL into your browser:
[link removed]
